{
  "report_rows": [
    {
      "kpi": "Adjusted EBITDA",
      "prediction": "BEAT",
      "answer": "pred ~$2.10B vs. cons $2.05B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Diluted EPS",
      "prediction": "IN-LINE",
      "answer": "pred ~$1.47 vs. cons $1.46",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue",
      "prediction": "MISS",
      "answer": "pred ~$9.15B vs. cons $9.40B",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Adjusted EBITDA guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$8.25B midpoint vs. cons $8.34B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Diluted EPS guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$5.53 midpoint vs. cons $5.70 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Capital expenditures guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$2.95B midpoint vs. cons $2.95B (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 1.8,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.4,
  "day5_path": "FADE",
  "day5_rationale": "A ~$2.10B Q2 EBITDA beat versus ~$2.05B consensus supports the initial move, but unchanged FY2026 EBITDA guidance of ~$8.25B versus ~$8.34B consensus implies softer second-half/out-period estimates, fading the day-1 residual from +1.8% to +0.4% cumulatively by day 5.",
  "day5_confidence": "MEDIUM"
}